keyword
MENU ▼
Read by QxMD icon Read
search

Afirma

keyword
https://www.readbyqxmd.com/read/28567111/cytomorphologic-features-distinguishing-bethesda-category-iv-thyroid-lesions-from-parathyroid
#1
Simon Sung, Anjali Saqi, Elizabeth M Margolskee, John P Crapanzano
BACKGROUND: Thyroid follicular cells share similar cytomorphological features with parathyroid. Without a clinical suspicion, the distinction between a thyroid neoplasm and an intrathyroidal parathyroid can be challenging. The aim of this study was to assess the distinguishing cytomorphological features of parathyroid (including intrathyroidal) and Bethesda category IV (Beth-IV) thyroid follicular lesions, which carry a 15%-30% risk of malignancy and are often followed up with surgical resection...
2017: CytoJournal
https://www.readbyqxmd.com/read/28544601/the-impact-of-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-on-the-performance-of-the-afirma-gene-expression-classifier
#2
Jen-Fan Hang, William H Westra, David S Cooper, Syed Z Ali
BACKGROUND: A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC). METHODS: The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed...
May 24, 2017: Cancer
https://www.readbyqxmd.com/read/28467214/evaluation-of-the-afirma-gene-expression-classifier-in-repeat-indeterminate-thyroid-nodules
#3
Grant Harrison, Julie Ann Sosa, Xiaoyin Jiang
CONTEXT: - Molecular testing in indeterminate thyroid nodules is a rapidly evolving field with variable reported outcomes. OBJECTIVE: - To report our experience at a tertiary thyroid referral center with the Afirma Gene Expression Classifier (Veracyte, San Francisco, California) in repeat fine-needle aspirations of thyroid nodules with a previous indeterminate cytologic result. DESIGN: - Results of cytopathology and the Afirma test were collected from August 2013 to March 2015, as were diagnoses from surgical resection when performed...
May 3, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28372589/the-first-canadian-experience-with-the-afirma%C3%A2-gene-expression-classifier-test
#4
Emily Kay-Rivest, Jamie Tibbo, Sarah Bouhabel, Michael Tamilia, Rebecca Leboeuf, Veronique-Isabelle Forest, Michael P Hier, Loren Savoury, Richard J Payne
BACKGROUND: Thyroid nodules are common and often benign, although prove to be malignant upon surgical pathology in 5-15% of cases. When assessed with ultrasound-guided fine-needle aspiration (USFNA), 15-30% of the nodules yield an indeterminate result. The Afirma® gene expression classifier (AGEC) was developed to improve management of indeterminate thyroid nodules (ITNs) by classifying them as "benign" or "suspicious." Objectives were (1) to assess the performance of the AGEC in two Canadian academic medical centres (2), to search for inter-institutional variation and (3) to compare AGEC performance in Canadian versus American institutions...
April 4, 2017: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/28371486/identification-of-parathyroid-tissue-in-thyroid-fine-needle-aspiration-a-combined-approach-using-cytology-immunohistochemical-and-molecular-methods
#5
Robert P Domingo, Lorna L Ogden, Laura C Been, Giulia C Kennedy, S Thomas Traweek
OBJECTIVES: Parathyroid (PT) lesions can be difficult to recognize in thyroid fine needle aspirations (FNAs), and when not identified correctly, PT cells may be mistaken for potentially abnormal thyroid cells. We therefore studied the utility of combining cytology, immunohistochemistry, and a molecular classifier to identify PT cells in thyroid FNAs. METHODS: Thyroid FNAs were received in CytoLyt, and were evaluated initially using The Bethesda System for Reporting Thyroid Cytology (TBSRTC)...
June 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28188700/how-suspicious-is-that-nodule-review-of-suspicious-afirma-gene-expression-classifier-in-high-risk-thyroid-nodules
#6
Sudarshana Roychoudhury, Melissa Klein, Fabiola Souza, Cecilia Gimenez, Alice Laser, Rubina Shaheen Cocker, Karen Chau, Kasturi Das
BACKGROUND: The Afirma gene expression classifier (GEC) is being increasingly utilized to confirm the benign nature of indeterminate FNA cytology results thus avoiding unnecessary surgical procedures. However the "suspicious" result of the Afirma GEC does not classify these indeterminate nodules further in determining appropriate management. This study investigated the outcome of the thyroid nodules deemed to be "suspicious" by the Afirma GEC in a high risk population. METHODS: The pathology database was searched for all thyroid nodules with Afirma test results over a three year period, 2013-2015...
April 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/28152275/qualifiers-of-atypia-in-the-cytologic-diagnosis-of-thyroid-nodules-are-associated-with-different-afirma-gene-expression-classifier-results-and-clinical-outcomes
#7
Sylvan C Baca, Kristine S Wong, Kyle C Strickland, Howard T Heller, Matthew I Kim, Justine A Barletta, Edmund S Cibas, Jeffrey F Krane, Ellen Marqusee, Trevor E Angell
BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) on fine-needle aspiration (FNA) have a low risk of malignancy that appears to vary based on specific features described in the AUS diagnosis. The Afirma gene expression classifier (GEC) is a molecular test designed to improve preoperative risk stratification of thyroid nodules, but its performance for different patterns of AUS has not been defined. The objective of this study was to assess GEC results and clinical outcomes in AUS nodules with architectural atypia (AUS-A), cytologic atypia (AUS-C) or both (AUS-C/A)...
February 2, 2017: Cancer
https://www.readbyqxmd.com/read/28003924/intrathyroidal-clear-cell-tumor-of-parathyroid-origin-with-review-of-literature
#8
Daniela Pirela, Daniela Treitl, Siba El Hussein, Robert Poppiti, Thomas Mesko, Alex Manzano
Water-clear cell adenoma (WCCA) of the parathyroid gland is an exceedingly rare neoplasm. To date, 17 cases have been reported in the literature, with only one of them being intrathyroidal. Here we report a case of a 34-year-old woman who presented for evaluation of a goiter and was found to have a thyroid nodule and abnormal thyroid function tests (TFT). Fine needle aspiration biopsy of the nodule revealed thyroid follicular cells without atypia and subsequent Afirma® Gene Expression Classifier (GEC) testing results were suspicious for malignancy...
2016: Case Reports in Pathology
https://www.readbyqxmd.com/read/27893191/young-investigator-challenge-molecular-testing-in-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features
#9
Xiaoyin Sara Jiang, Grant P Harrison, Michael B Datto
BACKGROUND: Molecular testing provides an important ancillary study for thyroid nodules with indeterminate cytology. The nomenclature shift to "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) will impact the performance of molecular tests. For the current study, the authors reviewed the performance of the Afirma gene-expression classifier (GEC) and the University of Pittsburgh Medical Center (UPMC) targeted mutation panel tests in thyroid nodules that were subsequently diagnosed as NIFTP on surgical resection...
December 2016: Cancer
https://www.readbyqxmd.com/read/27557410/molecular-testing-of-thyroid-nodules-a-review-of-current-available-tests-for-fine-needle-aspiration-specimens
#10
REVIEW
Ming Zhang, Oscar Lin
CONTEXT: - Fine-needle aspiration of thyroid nodules is a reliable diagnostic method to determine the nature of thyroid nodules. Nonetheless, indeterminate cytology diagnoses remain a diagnostic challenge. The development of multiplex molecular techniques and the identification of genetic alterations associated with different follicular cell-derived cancers in the thyroid have led to the introduction of several commercially available tests. OBJECTIVE: - To summarize the most common commercially available molecular testing in thyroid cancer, focusing on the technical features and test performance validation...
December 2016: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/27534929/usage-trends-and-performance-characteristics-of-a-gene-expression-classifier-in-the-management-of-thyroid-nodules-an-institutional-experience
#11
T Danielle Samulski, Virginia A LiVolsi, Lawrence Q Wong, Zubair Baloch
BACKGROUND: The gene expression classifier (GEC; Afirma-Veracyte) has proven to be an effective triage modality in the management of thyroid nodules. We evaluate our institutional experience with GEC, specifically examining performance as a first line testing strategy versus in conjunction with repeat fine needle aspiration (FNA), usage trends based on clinical setting, and performance related to diagnostic categories of The Bethesda System for Reporting Thyroid Cytology (TBSRTC). METHODS: All nodules undergoing GEC analysis from 1/2011 to 12/2015 at the Hospital of the University of Pennsylvania were identified using electronic database search methods...
November 2016: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27409819/utility-of-ultrasound-versus-gene-expression-classifier-in-thyroid-nodules-with-atypia-of-undetermined-significance
#12
Carmen V Villabona, Vineeth Mohan, Karla M Arce, Julia Diacovo, Alisha Aggarwal, Jessica Betancourt, Hassan Amer, Tessey Jose, Pascual DeSantis, Jose Cabral
OBJECTIVE: Thyroid nodules with fine-needle aspiration (FNA) cytology categorized as atypia of undetermined significance (AUS) often undergo additional diagnostic analysis with the Afirma Gene Expression Classifier (GEC), which classifies these as either high probability of being benign (GEC-B) or suspicious for malignancy (GEC-S). Our goal was to assess the clinical validity and utility of GEC in the evaluation of AUS cytology and evaluate the performance of ultrasonography (USG) for predicting malignancy in this subset...
October 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27347838/impact-of-afirma-gene-expression-classifier-on-cytopathology-diagnosis-and-rate-of-thyroidectomy
#13
Wendy L Sacks, Shikha Bose, Zachary S Zumsteg, Ronnie Wong, Stephen L Shiao, Glenn D Braunstein, Allen S Ho
BACKGROUND: The Afirma gene expression classifier (GEC) assesses malignancy risk in patients with indeterminate thyroid nodules. Afirma putatively reduces costs by classifying certain nodules as benign and thereby avoiding unnecessary surgery. Prior studies have evaluated its impact exclusively on GEC-tested nodules. The objective of the current study was to analyze the effect of Afirma on 1) cytopathology diagnosis, 2) the rate of surgery, and 3) the rate of malignancy on all indeterminate nodules at a high-volume thyroid center...
October 2016: Cancer
https://www.readbyqxmd.com/read/27344463/impact-of-the-afirma-gene-expression-classifier-result-on-the-surgical-management-of-thyroid-nodules-with-category-iii-iv-cytology-and-its-correlation-with-surgical-outcome
#14
Shweta Chaudhary, Yanjun Hou, Rulong Shen, Shveta Hooda, Zaibo Li
OBJECTIVE: The Afirma gene expression classifier (GEC) is a molecular test to further classify indeterminate fine-needle aspiration (FNA) as benign or suspicious for malignancy. STUDY DESIGN: A total of 158 FNAs with Bethesda category III/IV cytology were sent for an Afirma GEC test. We correlated the Afirma GEC results with surgical outcome and also compared the data after Afirma's implementation with the data before. RESULTS: Among the 158 FNAs, the Afirma result was benign in 63 (40%), suspicious in 85 (54%) and unsatisfactory in 10 (6%)...
2016: Acta Cytologica
https://www.readbyqxmd.com/read/27219469/noninvasive-follicular-variant-of-papillary-thyroid-carcinoma-and-the-afirma-gene-expression-classifier
#15
Kristine S Wong, Trevor E Angell, Kyle C Strickland, Erik K Alexander, Edmund S Cibas, Jeffrey F Krane, Justine A Barletta
BACKGROUND: It is now recognized that noninvasive follicular variant of papillary thyroid carcinoma (NFVPTC) is a distinct subset of FVPTC with an exceedingly indolent clinical course. The Afirma gene-expression classifier (GEC) helps guide clinicians in the management of thyroid nodules with indeterminate fine-needle aspiration (FNA) results. Thyroid surgery is recommended for nodules with a suspicious Afirma result, whereas observation is deemed reasonable for most nodules with a benign result...
July 2016: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/27124369/gene-expression-classifier-testing-and-the-surgical-decision-making-process-for-patients-with-thyroid-nodules-reply
#16
Salem I Noureldine, Martha A Zeiger, Ralph P Tufano
No abstract text is available yet for this article.
August 1, 2016: JAMA Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27102883/the-effect-of-implementing-gene-expression-classifier-on-outcomes-of-thyroid-nodules-with-indeterminate-cytology
#17
Jithma Prasad Abeykoon, Luke Mueller, Frank Dong, Ashish V Chintakuntlawar, Jonas Paludo, Rami Mortada
Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as "indeterminate" diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma® Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004-2014 were reviewed...
August 2016: Hormones & Cancer
https://www.readbyqxmd.com/read/26973059/impact-of-a-gene-expression-classifier-on-the-long-term-management-of-patients-with-cytologically-indeterminate-thyroid-nodules
#18
Joseph Singer, John W Hanna, Jay Visaria, Tao Gu, Mark McCoy, Richard T Kloos
OBJECTIVES: The gene expression classifier (GEC, Afirma ) reclassifies as molecularly benign approximately one half of thyroid nodule fine-needle aspiration (FNA) biopsies with an initial indeterminate cytopathology diagnosis, facilitating clinical monitoring in lieu of diagnostic thyroid surgery. This study evaluated the long-term management patterns and thyroid surgery rates of GEC benign patients compared to a control group of cytopathology benign patients and also described the costs of thyroid surgery...
July 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/26903551/institutional-prevalence-of-malignancy-of-indeterminate-thyroid-cytology-is-necessary-but-insufficient-to-accurately-interpret-molecular-marker-tests
#19
Pablo Valderrabano, Marino E Leon, Barbara A Centeno, Kristen J Otto, Laila Khazai, Judith C McCaffrey, Jeffery S Russell, Bryan McIver
OBJECTIVE: Several molecular marker tests are available to refine the diagnosis of thyroid nodules. Knowing the true prevalence of malignancy (PoM) within each cytological category is considered necessary to select the most appropriate test and to interpret results accurately. We describe our institutional PoM among cytological categories and report our experience with molecular markers. DESIGN: Single-center retrospective study. METHODS: We calculated the institutional PoM for each category of the Bethesda system (Bethesda) on all thyroid nodules with cytological evaluation from October 2008 to May 2014...
May 2016: European Journal of Endocrinology
https://www.readbyqxmd.com/read/26839268/ancillary-studies-in-thyroid-cytopathology
#20
REVIEW
N Paul Ohori, Karen E Schoedel
Recent advances in thyroid imaging, clinical evaluation, cytopathology, surgical pathology, and molecular diagnostics have contributed toward greater understanding of thyroid nodules. In particular, the development of the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) has brought standardization to the field and the system dovetails well with the implementation of immunohistochemistry and molecular testing to diagnostic practice. Among the molecular strategies available, the application of the molecular panel of common genetic alterations can stratify indeterminate BSRTC diagnoses into low-risk and high-risk groups...
March 2014: Surgical Pathology Clinics
keyword
keyword
109064
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"